The growth was driven by volume growth in the specialized and wellness segments, as well as B2C revenue growth. The improved operating margins were on account of higher revenues leading to operating leverage & product mix.

The company also saw a reduction in competitive intensity and an increase in prices by multiple peers in the diagnostics industry. With its swift actions, strategic initiatives & network expansion strategies, the company is well-positioned to capitalize on these positive developments.

The company's gross debt as on 30 September 2023 stood at Rs 44 crore.

Metropolis Healthcare is a diagnostics company, with presence in 20 states & 220 cities. Internationally, the company has presence in South Asia, Africa, and the Middle East. It offers a comprehensive range of 4,000 plus tests and profiles that include advanced tests in diagnosis of cancer, neurological disorders, infectious diseases, and an array of genetic abnormalities. The company has a network of over 180 labs, 3,730 collection centres and over 10,000 touch points.

The company had reported 13.8% fall in consolidated net profit to Rs 28.80 crore on 1% decline in net sales to Rs 277.09 crore in Q1 FY24 over Q1 FY23.